TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

TransMedics Group (TMDX) announced the granting of inducement awards to three new employees on March 28, 2025. The compensation package includes:

• 1,570 non-qualified stock options with an exercise price of $68.58 per share
• 1,043 restricted stock units (RSUs)

The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Inducement Plan.

ANDOVER, Mass., April 2, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on March 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 1,570 shares of its common stock and an aggregate of 1,043 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

TransMedics granted non-qualified stock options to purchase 1,570 shares of TransMedics' common stock and 1,043 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $68.58, the closing price of the common stock on the Nasdaq Global Market on March 28, 2025. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the Company through the applicable vesting date. The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302418969.html

SOURCE TransMedics Group, Inc.

FAQ

What is the vesting schedule for TransMedics (TMDX) inducement stock options granted in March 2025?

The stock options vest 25% after first year, with remaining portions vesting monthly over three years, requiring continued employment.

How many shares were included in TransMedics (TMDX) March 2025 inducement grants?

TransMedics granted 1,570 stock options and 1,043 restricted stock units to three employees.

What is the exercise price for TMDX stock options granted on March 28, 2025?

The stock options were granted with an exercise price of $68.58, matching the closing price on Nasdaq Global Market.

What is the vesting schedule for TMDX restricted stock units granted in March 2025?

The RSUs vest 25% annually over four years, subject to continued employment.